AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 18, 2023
A type of bacteria commonly found in human oral and gut flora could play a major role in the development of endometriosis, scientists have discovered – potentially giving us crucial insight into the development of the painful condition, and opening up new ways to treat it.
BioSpace
JUNE 18, 2023
On the heels of a legal challenge to the Inflation Reduction Act by Merck, Bristol Myers Squibb on Friday filed its own lawsuit claiming that the law’s drug price negotiation provision is unconstitutional.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 18, 2023
Rani’s ‘robotic’ pill delivers injectable osteoporosis drug Phil.
BioSpace
JUNE 18, 2023
In the first head-to-head trial of CGRP antagonists, Lilly’s Emgality failed to demonstrate that it was significantly better than Pfizer’s Nurtec ODT at easing migraine headaches.
The Pharma Data
JUNE 18, 2023
People with medical needs are “left behind in pain” reveals new report The World Health Organization (WHO) has published a new report on access to morphine for medical use, which describes how the global distribution of morphine, as a vital pain medicine, is unequal and does not fulfil the medical need. The report, titled “Left behind in pain”, highlights the problems in access to this essential medicine and offers actions to improve safe access through balanced policy.
BioSpace
JUNE 18, 2023
Scott Rivers, president and managing partner of an executive search and talent branding firm, weighs in on what managers can do to keep top talent.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
JUNE 18, 2023
Following disappointing Phase IIb results, BioSenic is pausing the development of its tibial fracture cell therapy ALLOB derived from mesenchymal stem cells.
The Pharma Data
JUNE 18, 2023
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality ® (galcanezumab-gnlm) and Nurtec ® ODT (rimegepant orally disintegrating tablet), the first and only trial of its kind comparing two calcitonin gene-related peptide (CGRP) antagonist therapies.
BioSpace
JUNE 18, 2023
The Bespoke Gene Therapy Consortium intends to bring AAV-based gene therapies to patients whose diseases are often ignored by commercial interests.
Drug Patent Watch
JUNE 18, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
JUNE 18, 2023
Jubilant Therapeutics's differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.
Pharmaceutical Technology
JUNE 18, 2023
Cholesgen (Shanghai) has announced a three-year partnership with AstraZeneca to advance research and development (R&D) in hypercholesterolemia and related metabolic diseases. The companies will validate genetic drug targets and advance therapeutic molecules into clinical development. By leveraging their complementary strengths, they will focus on selected targets from the early stage portfolios of Cholesgen.
Expert insights. Personalized for you.
236 
Let's personalize your content